Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SABS
stocks logo

SABS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.080
-93.5%
--
--
-0.074
-86.79%
--
--
-0.076
-93.03%
Estimates Revision
The market is revising No Change the revenue expectations for SAB Biotherapeutics, Inc. (SABS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 67.40%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-99.9%
In Past 3 Month
Stock Price
Go Up
up Image
+67.40%
In Past 3 Month
Wall Street analysts forecast SABS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SABS is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast SABS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SABS is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.800
sliders
Low
7.00
Averages
8.00
High
9.00
Current: 3.800
sliders
Low
7.00
Averages
8.00
High
9.00
Leerink
Outperform
initiated
$7
2025-09-17
Reason
Leerink
Price Target
$7
2025-09-17
initiated
Outperform
Reason
Leerink initiated coverage of SAB Biotherapeutics with an Outperform rating and $7 price target. SAB is a clinical-stage biotech focused on the development of lead asset SAB-142 - a first-in-class, human, multi-target anti-thymocyte globulin aimed at preventing or delaying progression of Type 1 Diabetes. The firm views SAB-142's mechanism as partially derisked in T1D based on multiple clinical studies evaluating rabbit ATG, which has shown an ability to preserve an important biomarker of beta cell function and delay T1D progression. Leerink sees ample commercial opportunity for SAB-142 based on MEDACorp KOL feedback highlighting the significant unmet need among newly diagnosed T1D patients and lack of approved therapies for delaying or preventing progression of the disease.
Chardan
Buy
downgrade
$20 -> $12
2025-08-08
Reason
Chardan
Price Target
$20 -> $12
2025-08-08
downgrade
Buy
Reason
Chardan lowered the firm's price target on SAB Biotherapeutics to $12 from $20 and keeps a Buy rating on the shares after the company reported Q2 results. A recent financing will fund the potentially pivotal Phase IIb SAFEGUARD trial of SAB-142 in type I diabetes, notes the analyst, who cites dilution from the fundraising for the company's lowered target.
H.C. Wainwright
initiated
$10
2025-05-14
Reason
H.C. Wainwright
Price Target
$10
2025-05-14
initiated
Reason
H.C. Wainwright assumed coverage of SAB Biotherapeutics with a Buy rating and $10 price target. Following a positive topline data readout in healthy volunteers that showcased sustained immunomodulation and a clean safety profile, SAB's human anti-thymocyte immunoglobulin, SAB-142, is positioning itself as a potential new immunotherapy to prevent and control the progression of type 1 diabetes, the analyst tells investors in a research note.
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$6
2025-04-01
Reason
HC Wainwright & Co.
Edward White
Price Target
$6
2025-04-01
Reiterates
Strong Buy
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$25 → $20
2025-04-01
Reason
Chardan Capital
Keay Nakae
Price Target
$25 → $20
2025-04-01
Maintains
Strong Buy
Reason
Chardan analyst Keay Nakae lowered the firm's price target on SAB Biotherapeutics to $20 from $25 and keeps a Buy rating on the shares after the company reported its Q4 and full year results. The company remains on track to initiate the Phase 2 SAFEGUARD clinical study to evaluate SAB-142, notes the analyst, who lowered the firm's price target to reflect a higher projected future share count as modeled future capital raises, including one in Q2, are expected to be more dilutive due to the current share price.
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$6
2025-01-29
Reason
HC Wainwright & Co.
Edward White
Price Target
$6
2025-01-29
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for SAB Biotherapeutics Inc (SABS.O) is -12.34, compared to its 5-year average forward P/E of -9.46. For a more detailed relative valuation and DCF analysis to assess SAB Biotherapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.46
Current PE
-12.34
Overvalued PE
5.84
Undervalued PE
-24.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
46.72
Current PS
0.00
Overvalued PS
140.22
Undervalued PS
-46.78
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 10058566.67% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SABS News & Events

Events Timeline

(ET)
2025-09-19
07:28:17
SAB Biotherapeutics Showcases Data Through Various Presentations at EASD
select
2025-08-07 (ET)
2025-08-07
07:43:00
SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year
select
2025-07-21 (ET)
2025-07-21
07:38:57
SAB Biotherapeutics announces oversubscribed $175M private placement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-14Newsfilter
SAB BIO Announces Financial Results for Third Quarter and Key Business Updates

  • Initiation of SAFEGUARD Trial: SAB Biotherapeutics has launched the registrational Phase 2b SAFEGUARD trial for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, with plans to dose the first patient by year-end.

  • Clinical Data Presentation: Recent presentations at EASD and ISPAD highlighted the favorable safety profile and multi-specific mechanism of action of SAB-142, reinforcing its potential as a disease-modifying treatment for T1D.

  • Financial Position: As of September 30, 2025, SAB Biotherapeutics reported a strong cash position of $161.5 million, enabling continued investment in the SAB-142 program and other research activities.

  • Upcoming Milestones: The company is on track to share additional data from the SAFEGUARD trial in the second half of 2027 and finalize Phase 1 study results by the end of this year.

[object Object]
Preview
9.0
09-19Newsfilter
SAB BIO Showcases Data Through Various Presentations at EASD

  • SAB-142 Phase 2b Study Initiation: SAB Biotherapeutics has launched its Phase 2b SAFEGUARD study for SAB-142, targeting new-onset Stage 3 autoimmune type 1 diabetes (T1D) patients, and engaged with T1D thought leaders at the EASD Annual Meeting.

  • Validation of SAB-142's Efficacy: Presentations at EASD highlighted SAB-142's potential as a best-in-class immunotherapy for T1D, demonstrating a clinically validated mechanism of action and favorable pharmacokinetic profile, while also confirming the disease-modifying effects of rabbit ATG in a related study.

[object Object]
Preview
4.0
09-18NASDAQ.COM
Leerink Partners Begins Coverage of SAB Biotherapeutics (SABS) with a Positive Outlook

  • Coverage Initiation: Leerink Partners initiated coverage of SAB Biotherapeutics with an "Outperform" recommendation, projecting a significant upside of 336.47% based on an average one-year price target of $9.38/share.

  • Fund Sentiment: There has been a slight decrease in institutional ownership, with 34 funds reporting positions in SAB Biotherapeutics, while total shares owned by institutions decreased by 12.93% over the last three months.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is SAB Biotherapeutics Inc (SABS) stock price today?

The current price of SABS is 3.8 USD — it has increased 2.7 % in the last trading day.

arrow icon

What is SAB Biotherapeutics Inc (SABS)'s business?

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

arrow icon

What is the price predicton of SABS Stock?

Wall Street analysts forecast SABS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SABS is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is SAB Biotherapeutics Inc (SABS)'s revenue for the last quarter?

SAB Biotherapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is SAB Biotherapeutics Inc (SABS)'s earnings per share (EPS) for the last quarter?

SAB Biotherapeutics Inc. EPS for the last quarter amounts to -0.21 USD, decreased -81.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for SAB Biotherapeutics Inc (SABS)'s fundamentals?

The market is revising No Change the revenue expectations for SAB Biotherapeutics, Inc. (SABS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 67.40%.
arrow icon

How many employees does SAB Biotherapeutics Inc (SABS). have?

SAB Biotherapeutics Inc (SABS) has 63 emplpoyees as of December 05 2025.

arrow icon

What is SAB Biotherapeutics Inc (SABS) market cap?

Today SABS has the market capitalization of 180.91M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free